随着时间的推移,梅特福林对维生素B12缺乏症的影响 (EMBER):一个真实世界的证据数据库研究
Keri Hurley-Kim1, Chuong Hoang Vu2, Nhat Minh Dao2
1Department of Clinical Pharmacy Practice, University of California, Irvine School of Pharmacy & Pharmaceutical Sciences, Irvine, California.
概括
在2型糖尿病中长期使用甲福林会增加维生素B12缺乏的风险. 这种风险随着甲福明使用的每年增加,特别是四年后.
科学领域:
- 内分泌学和新陈代谢学
- 营养科学 营养科学
- 药理学 药理学是指药理学的学科.
背景情况:
- 甲福明是2型糖尿病 (T2DM) 的一线治疗方法.
- 维生素B12缺乏是甲福林治疗的一个潜在问题.
- 甲福明对维生素B12水平的长期影响需要进一步研究.
研究的目的:
- 在T2DM患者中调查甲福明使用与维生素B12缺乏症之间的关联.
- 为了评估长期使用甲福林时发展维生素B12缺乏症的风险.
- 评估甲胺对边界维生素B12缺乏症的影响.
主要方法:
- 对成年T2DM患者的"我们所有人"数据库的分析,有记录使用甲福明的成年患者.
- 排除以前存在维生素B12缺乏症的参与者.
- 后勤回归模型来评估美特福林持续时间和B12缺乏风险之间的关联.
主要成果:
- 分析了超过36,000名T2DM参与者;16.9%的人使用了甲胺.
- 与非使用者 (6.3%) 相比,梅特福林使用者的B12缺乏率更高 (7.5%).
- 长期使用甲素 (≥4年) 显著增加了B12缺乏 (41.0%) 和边缘缺乏 (27.0%) 的几率.
结论:
- 长期使用甲福明与T2DM患者维生素B12缺乏的风险增加有关.
- 维生素B12缺乏症的风险随着甲福林治疗的持续时间逐渐增加.
- 临床医生应监测长期接受甲福林治疗的患者的维生素B12水平.
相关概念视频
Vitamins
774
Vitamins, derived from the Latin word for life, are essential organic substances required in small quantities for optimal growth and overall well-being. Unlike other organic nutrients, vitamins don't act as sources of energy or building materials but rather facilitate these nutrients' utilization by the body. Vitamins are predominantly coenzymes, assisting enzymes in specific chemical actions, like the oxidation of glucose for energy involving B vitamins. Most vitamins are not produced...
774
Oral Hypoglycemic Agents: Biguanides and Glitazones
230
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
230
Insulin: Dosing Regimen and Adverse Effects
205
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
205
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
195
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
195
Inborn Errors of Metabolism
194
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
194
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K


